Abstract: ObjectiveTo observe and evaluate the clinical efficacy of recombinant human IFN-γ in multidrug-resistant pulmonary tuberculosis(MDR-TB).MethodsSisty cases with MDR-TB were randomized into a treatment group(30 cases treated with 3SPPZETH+(2)IFN-γ/9SPPE) and a control group（30 cases treated with 3SpPaZETH/9SpPaE）. IFN-γ was used by aerosilizing inhalation in initial phase of the treatment group for two months. Results28 cases in the treatment group and 29 cases in the control group completed the treatment course.The sputum negative conversion rate in the treatment group（82.1%）was higher than that in the control group（58.6%）(P<0.05).The rate of radiographic improvement in the treatment group(92.9%) was higher than that in the control group(P<0.01).CD4 T cells count and the ratio of CD4/CD8 in the treatment group were higher than that in the control group at the 3nd month of therapy (P<0.05). There was no severe adverse effects of IFN-γ therapy. ConclusionsAs an effective and relatively safe biological agent, IFN-γ can be used to adjuvant therapy in multidrug-resistant pulmonary tuberculosis.

Key words: tuberculosis,multidrug-resistan/drug therapy, interferon-gamma,recombinant, insufflation